Improving the Capture of Adverse Event Data in Clinical Trials: The Role of the International Atomic Energy Agency

Susan E. Davidson, Andy Trotti, Özlem U. Ataman, Jinsil Seong, Fen Nee Lau, Neiro W. da Motta, Branislav Jeremic

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Purpose: To report meetings of the Applied Radiation Biology and Radiotherapy section of the International Atomic Energy Agency (IAEA), organized to discuss issues surrounding, and develop initiatives to improve, the recording of adverse events (AE) in clinical trials. Methods and Materials: A first meeting was held in Atlanta, GA (October 2004). A second meeting was held in Denver, CO (October 2005) and focused on AE data capture. The National Cancer Institute Common Terminology Criteria for Adverse Events, version 3 (CTCAE) was suggested during the first meeting as the preferred common platform for the collection and reporting of AE data in its clinical trials. The second meeting identified and reviewed the current weaknesses and variations in the capture of AE data, and proposals to improve the quality and consistency of data capture were discussed. Results: There is heterogeneity in the collection of AE data between both institutions and individual clinicians. The use of multiple scoring systems hampers comparisons of treatment outcomes between centers and trials. There is often insufficient detail on normal tissue treatment effects, which leads to an underestimate of toxicity. Implementation of improved data capture was suggested for one of the ongoing IAEA clinical trials. Conclusions: There is a need to compare the quality and completeness of data between institutions and the efficacy of structured/directed vs. traditional passive data collection. Data collection using the CTCAE (with or without a questionnaire) will be investigated in an IAEA multinational trial of radiochemotherapy and high-dose-rate brachytherapy in cervical cancer.

Original languageEnglish
Pages (from-to)1218-1221
Number of pages4
JournalInternational Journal of Radiation Oncology Biology Physics
Volume69
Issue number4
DOIs
Publication statusPublished - 2007 Nov 15

Fingerprint

Nuclear Energy
nuclear energy
Clinical Trials
Terminology
Radiobiology
National Cancer Institute (U.S.)
Brachytherapy
Chemoradiotherapy
Carbon Monoxide
terminology
Uterine Cervical Neoplasms
Radiotherapy
Atlanta (GA)
cancer
scoring
completeness
biology
toxicity
proposals
radiation therapy

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Davidson, Susan E. ; Trotti, Andy ; Ataman, Özlem U. ; Seong, Jinsil ; Lau, Fen Nee ; da Motta, Neiro W. ; Jeremic, Branislav. / Improving the Capture of Adverse Event Data in Clinical Trials : The Role of the International Atomic Energy Agency. In: International Journal of Radiation Oncology Biology Physics. 2007 ; Vol. 69, No. 4. pp. 1218-1221.
@article{ce53223ca5b6457da8e9e04e2d1f819a,
title = "Improving the Capture of Adverse Event Data in Clinical Trials: The Role of the International Atomic Energy Agency",
abstract = "Purpose: To report meetings of the Applied Radiation Biology and Radiotherapy section of the International Atomic Energy Agency (IAEA), organized to discuss issues surrounding, and develop initiatives to improve, the recording of adverse events (AE) in clinical trials. Methods and Materials: A first meeting was held in Atlanta, GA (October 2004). A second meeting was held in Denver, CO (October 2005) and focused on AE data capture. The National Cancer Institute Common Terminology Criteria for Adverse Events, version 3 (CTCAE) was suggested during the first meeting as the preferred common platform for the collection and reporting of AE data in its clinical trials. The second meeting identified and reviewed the current weaknesses and variations in the capture of AE data, and proposals to improve the quality and consistency of data capture were discussed. Results: There is heterogeneity in the collection of AE data between both institutions and individual clinicians. The use of multiple scoring systems hampers comparisons of treatment outcomes between centers and trials. There is often insufficient detail on normal tissue treatment effects, which leads to an underestimate of toxicity. Implementation of improved data capture was suggested for one of the ongoing IAEA clinical trials. Conclusions: There is a need to compare the quality and completeness of data between institutions and the efficacy of structured/directed vs. traditional passive data collection. Data collection using the CTCAE (with or without a questionnaire) will be investigated in an IAEA multinational trial of radiochemotherapy and high-dose-rate brachytherapy in cervical cancer.",
author = "Davidson, {Susan E.} and Andy Trotti and Ataman, {{\"O}zlem U.} and Jinsil Seong and Lau, {Fen Nee} and {da Motta}, {Neiro W.} and Branislav Jeremic",
year = "2007",
month = "11",
day = "15",
doi = "10.1016/j.ijrobp.2007.04.054",
language = "English",
volume = "69",
pages = "1218--1221",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

Improving the Capture of Adverse Event Data in Clinical Trials : The Role of the International Atomic Energy Agency. / Davidson, Susan E.; Trotti, Andy; Ataman, Özlem U.; Seong, Jinsil; Lau, Fen Nee; da Motta, Neiro W.; Jeremic, Branislav.

In: International Journal of Radiation Oncology Biology Physics, Vol. 69, No. 4, 15.11.2007, p. 1218-1221.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improving the Capture of Adverse Event Data in Clinical Trials

T2 - The Role of the International Atomic Energy Agency

AU - Davidson, Susan E.

AU - Trotti, Andy

AU - Ataman, Özlem U.

AU - Seong, Jinsil

AU - Lau, Fen Nee

AU - da Motta, Neiro W.

AU - Jeremic, Branislav

PY - 2007/11/15

Y1 - 2007/11/15

N2 - Purpose: To report meetings of the Applied Radiation Biology and Radiotherapy section of the International Atomic Energy Agency (IAEA), organized to discuss issues surrounding, and develop initiatives to improve, the recording of adverse events (AE) in clinical trials. Methods and Materials: A first meeting was held in Atlanta, GA (October 2004). A second meeting was held in Denver, CO (October 2005) and focused on AE data capture. The National Cancer Institute Common Terminology Criteria for Adverse Events, version 3 (CTCAE) was suggested during the first meeting as the preferred common platform for the collection and reporting of AE data in its clinical trials. The second meeting identified and reviewed the current weaknesses and variations in the capture of AE data, and proposals to improve the quality and consistency of data capture were discussed. Results: There is heterogeneity in the collection of AE data between both institutions and individual clinicians. The use of multiple scoring systems hampers comparisons of treatment outcomes between centers and trials. There is often insufficient detail on normal tissue treatment effects, which leads to an underestimate of toxicity. Implementation of improved data capture was suggested for one of the ongoing IAEA clinical trials. Conclusions: There is a need to compare the quality and completeness of data between institutions and the efficacy of structured/directed vs. traditional passive data collection. Data collection using the CTCAE (with or without a questionnaire) will be investigated in an IAEA multinational trial of radiochemotherapy and high-dose-rate brachytherapy in cervical cancer.

AB - Purpose: To report meetings of the Applied Radiation Biology and Radiotherapy section of the International Atomic Energy Agency (IAEA), organized to discuss issues surrounding, and develop initiatives to improve, the recording of adverse events (AE) in clinical trials. Methods and Materials: A first meeting was held in Atlanta, GA (October 2004). A second meeting was held in Denver, CO (October 2005) and focused on AE data capture. The National Cancer Institute Common Terminology Criteria for Adverse Events, version 3 (CTCAE) was suggested during the first meeting as the preferred common platform for the collection and reporting of AE data in its clinical trials. The second meeting identified and reviewed the current weaknesses and variations in the capture of AE data, and proposals to improve the quality and consistency of data capture were discussed. Results: There is heterogeneity in the collection of AE data between both institutions and individual clinicians. The use of multiple scoring systems hampers comparisons of treatment outcomes between centers and trials. There is often insufficient detail on normal tissue treatment effects, which leads to an underestimate of toxicity. Implementation of improved data capture was suggested for one of the ongoing IAEA clinical trials. Conclusions: There is a need to compare the quality and completeness of data between institutions and the efficacy of structured/directed vs. traditional passive data collection. Data collection using the CTCAE (with or without a questionnaire) will be investigated in an IAEA multinational trial of radiochemotherapy and high-dose-rate brachytherapy in cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=35448982830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35448982830&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.04.054

DO - 10.1016/j.ijrobp.2007.04.054

M3 - Article

C2 - 17689027

AN - SCOPUS:35448982830

VL - 69

SP - 1218

EP - 1221

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -